University Hospital of Cologne
Welcome,         Profile    Billing    Logout  
 41 Trials 
78 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gouni-Berthold, Ioanna
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
Mattar, Andre
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
WEFITTER, NCT05277935: Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib

Recruiting
N/A
68
RoW
Use of the WeCancer app combined with the smartwatch.
Beneficência Portuguesa de São Paulo
Breast Neoplasm Female, Quality of Life
03/25
03/25
Contact, Central
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Completed
4
52
RoW
Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT)
Astellas Pharma Inc
Metastatic Castration Resistant Prostate Cancer
02/24
02/24
NCT03684018 / 2018-003430-33: Two Dose Levels of Privigen in Pediatric CIDP

Recruiting
4
30
US
IgPro10, Privigen
CSL Behring
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
12/29
12/29
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Completed
3
395
RoW
Enzalutamide, Xtandi, MDV3100, Placebo
Astellas Pharma Inc
Progressive Metastatic Prostate Cancer
09/15
07/24
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

Recruiting
3
177
Canada, US
IgPro20, HIZENTRA®, Placebo
CSL Behring
Post-COVID Postural Orthostatic Tachycardia Syndrome
09/27
09/27
NCT06617897: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery

Recruiting
3
90
Europe
CSL511 Fibrinogen concentrate (human), Cryoprecipitate
CSL Behring
Acquired Fibrinogen Deficiency
09/26
10/26
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study )

Terminated
3
1370
Europe, US, RoW
BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo
CSL Behring
Traumatic Injury
10/24
10/24
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation

Active, not recruiting
2
100
RoW
Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032
Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU
Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers
07/15
05/18
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors

Active, not recruiting
2
152
RoW
Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA)
Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer
Solid Tumors, Colorectal Cancer
04/18
09/18
HERALD, NCT06342947: ALG-055009 in Non-cirrhotic Adults With MASH

Active, not recruiting
2
100
US
ALG-055009, Placebo
Aligos Therapeutics
NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis
11/24
12/24
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder

Recruiting
2
200
US
Sunobinop, V117957, Placebo to match sunobinop
Imbrium Therapeutics, Purdue Pharma LP
Alcohol Use Disorder
07/25
07/25
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Completed
1
47
US
V117957, Placebo
Imbrium Therapeutics, Purdue Pharma LP
Interstitial Cystitis/Bladder Pain Syndrome
01/25
01/25
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Completed
1
28
Europe, US
CSL889
CSL Behring
Sickle Cell Disease
07/23
07/23
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors

Checkmark Comparison of subcutaneous talazoparib versus oral talazoparib
Feb 2018 - Feb 2018: Comparison of subcutaneous talazoparib versus oral talazoparib
Withdrawn
1
10
RoW
Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib
Center Trials & Treatment, BioGene Pharmaceutical
Advanced or Recurrent Solid Tumors, Breast Neoplasm
12/23
01/24
PRL-02-1001, NCT04729114: A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Recruiting
1
174
US
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Astellas Pharma Global Development, Inc.
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
08/25
05/29
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors

Recruiting
1
175
US
ASP4396
Astellas Pharma Inc
Solid Tumor
04/27
04/27
NCT06171178: A Study of ASP1012 in Adults With Solid Tumors

Recruiting
1
229
US
ASP1012, Pembrolizumab
Astellas Pharma Global Development, Inc.
Solid Tumor
06/29
06/29
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas

Terminated
1
1
RoW
ASP2802, MACT, MA-20, ASP101G, MicAbody
Astellas Pharma Global Development, Inc.
B-cell Lymphoma
12/24
12/24
NCT06024642: Study of V117957 in Overactive Bladder Syndrome

Completed
1
51
US
V117957, Placebo
Imbrium Therapeutics, Purdue Pharma LP
Overactive Bladder Syndrome
05/24
05/24
NCT03292887: Hunter Outcome Survey (HOS)

Completed
N/A
1443
US
Shire
Hunter Syndrome
02/23
02/23
NCT05104840: A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus

Terminated
N/A
2432
US, RoW
Center Trials & Treatment, Oleg Martynenko
COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE)
03/23
03/23
NCT03291223: Gaucher Disease Outcome Survey (GOS)

Recruiting
N/A
1257
US
Shire
Gaucher Disease
09/25
09/25
NCT06734585: Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Recruiting
N/A
200
RoW
Gilteritinib, ASP2215, XOSPATA®
Astellas Pharma Singapore Pte. Ltd.
Acute Myeloid Leukemia
06/25
06/25
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats

Recruiting
N/A
1000
US
Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above
Astellas Pharma Global Development, Inc.
Hot Flashes
02/26
11/26
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Recruiting
N/A
3000
Japan
Peficitinib, ASP015K, Smyraf
Astellas Pharma Inc
Rheumatoid Arthritis (RA)
12/25
12/25
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens

Active, not recruiting
N/A
249
RoW
Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens
HOYA Lens Thailand LTD.
Myopia
05/26
05/27
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection

Recruiting
N/A
202
RoW
Enfortumab Vedotin, PADCEV, ASG-22CE
Astellas Pharma Korea, Inc., Seagen Inc.
Urothelial Cancer
07/27
07/27
CPEVLN, NCT04792632: Clinical Performance Evaluation of Veye Lung Nodules

Recruiting
N/A
350
US
Veye Lung nodules
Aidence
Lung; Node
07/21
07/21
Reuter, Hannes
NCT02880631: BAROSTIM THERAPY™ In Resistant Hypertension

Recruiting
N/A
500
Europe
BAROSTIM NEO™ System
CVRx, Inc.
Hypertension
07/24
07/24
MOREL, Jacques
SUNSTAR, NCT03227419 / 2017-000947-41: Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders

Recruiting
4
224
Europe
Tocilizumab Prefilled Syringe, RoActemra, Abatacept Prefilled Syringe, Orencia
Lille Catholic University
Arthritis, Rheumatoid
09/24
11/24
SEQUENS-RA, NCT05428488: Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis

Recruiting
3
220
Europe, RoW
Abatacept (W12-W48), TNF Inhibitor (W12-W48), TNF Inhibitor (W0-W12)
University Hospital, Montpellier
Rheumatoid Arthritis
11/24
11/25
CRI-RA, NCT04870203: Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis

Recruiting
3
178
Europe, RoW
baricitinib treatment, adalimumab, Placebo
University Hospital, Bordeaux, Eli Lilly and Company, Biogen, Ministry for Health and Solidarity, France
Rheumatoid Arthritis
12/25
12/25
BACHELOR, NCT04027101: BAriCitinib Healing Effect in earLy pOlymyalgia Rheumatica

Completed
2
34
Europe
Baricitinib, Placebos
University Hospital, Brest, Eli Lilly and Company
Polymyalgia Rheumatic (PMR)
08/23
08/23
NECESSITY, NCT05113004: New Clinical End-points in Patients With Primary Sjögren's Syndrome

Recruiting
2
300
Europe
Hydroxychloroquine 400mg/d, Leflunomide 20mg/d, Mycophenolate mofetil 2000mg/d, Placebo of Hydroxychloroquine 400mg/d, Placebo of Leflunomide 20mg/d, Placebo of Mycophenolate mofetil 2000mg/d
Assistance Publique - Hôpitaux de Paris
Primary Sjögren's Syndrome (pSS)
04/25
10/25
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
METorMET², NCT04196868: Methotrexate and Metformin in Rheumatoid Arthritis Patients

Active, not recruiting
2
128
Europe
Metformin treatment, Placebo, Methotrexate treatment
University Hospital, Bordeaux, Ministry for Health and Solidarity, France
Arthritis, Rheumatoid
06/26
06/26
SCLERITA, NCT04789850: Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis

Recruiting
2
74
Europe
Itacitinib, Placebo
Assistance Publique - Hôpitaux de Paris
Systemic Sclerosis
02/26
02/26
EMOPTION, NCT04798053: Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients

Completed
N/A
259
Europe
Questionnaire, blood sample and salivary sample
University Hospital, Bordeaux, Societe Francaise de Rhumatologie
Covid19, Rheumatic Fever, Mental Disorder
12/22
12/22
GlutenSPA, NCT04274374: Impact of a Gluten-free Diet on Quality of Life in Patients With Axial Spondyloarthritis.

Recruiting
N/A
200
Europe
Gluten-Free Diet, Gluten Diet
University Hospital, Clermont-Ferrand, PANZANI, Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement
Ankylosing Spondyloarthritis
10/25
03/26
RESPOND-IL17, NCT05812157: Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis -

Recruiting
N/A
36
Europe
Daily dietary supplementation with Fibruline, Anti-IL-17 therapy
Centre Hospitalier Universitaire de Nīmes
Axial Spondyloarthritis
12/26
12/26
NCT03642795: Validation of the French Version of the CQR (Compliance Questionnaire Rheumatology)

Recruiting
N/A
150
Europe
Questionnaire
Centre Hospitalier Universitaire de Nīmes
Rheumatoid Polyarthritis
09/27
09/27
Schewior, Tatjana
NCT02880631: BAROSTIM THERAPY™ In Resistant Hypertension

Recruiting
N/A
500
Europe
BAROSTIM NEO™ System
CVRx, Inc.
Hypertension
07/24
07/24
NCT02876042: BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction

Recruiting
N/A
70
Europe
BAROSTIM NEO™ System
CVRx, Inc.
Heart Failure
07/24
07/24
Kofler, David
TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting
3
540
Europe, Canada, Japan, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/25
03/26
NCT05436652 / 2022-000299-20: A Trial of Prednisolone in Combination With SPI-62 or Placebo in Subjects With Polymyalgia Rheumatica (PMR)

Recruiting
2
72
Europe
SPI-62, SPI-62 matched placebo, Prednisolone 10mg, Additional prednisolone, Additional prednisolone matched placebo
Sparrow Pharmaceuticals
Polymyalgia Rheumatica
04/25
07/25
PASTOR, NCT04062695 / 2018-004254-22: Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement

Recruiting
2
80
Europe
Tofacitinib 5 MG Oral Tablet [Xeljanz], Xeljanz, Placebo oral tablet
Charite University, Berlin, Germany, Pfizer Pharma GmbH, unrestricted grant
Psoriatic Arthritis, Spondylitis, Sacroilitis
12/23
12/23
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
SunStone, NCT06559163: A Study of Obexelimab in Patients with Systemic Lupus Erythematosus

Recruiting
2
190
Europe, Japan, US, RoW
Obexelimab, Placebo
Zenas BioPharma (USA), LLC
Systemic Lupus Erythematosus
06/26
09/26
Malter, Wolfram
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
CATCH, NCT05652569: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer

Recruiting
N/A
5000
Europe
Genomic Profiling / Sequencing
German Cancer Research Center, University Hospital Heidelberg
Metastatic Breast Cancer
12/30
12/30
Purnell, Peter Walter
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Active, not recruiting
3
405
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteo Arthritis Knee
12/25
12/25
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Active, not recruiting
3
1000
Europe, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
05/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Exman, Pedro
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
SCHOLAR-2, NCT04680442: Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

Recruiting
2
130
Canada, RoW
Trastuzumab, Herceptin, Herzuma, Ogivri, Trazimera, Kanjinti, Pertuzumab, Perjeta, Trastuzumab emtansine, Kadcyla,
Population Health Research Institute
Breast Cancer, Heart Failure
01/25
06/25
Meneguetti, Renata Tortato
AddChemo, NCT05764044: Adjuvant Chemotherapy in cfHPV-DNA Plasma Positive Patients: A Biomarker In Locally Advanced Cervical Cancer

Recruiting
3
365
RoW
cisplatin, gemcitabine, Follow-up
Hospital do Coracao, University of Sao Paulo
Cervical Cancer, Cervix Cancer, Cervix Neoplasm
12/26
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
TACX Care, NCT04833998: Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine

Recruiting
2
54
RoW
Extremecare, Placebo
Instituto Brasileiro de Controle do Cancer, Wecare Comércio de Cosméticos
Hand-foot Syndrome
11/21
12/21
Budak-Alpdogan, Tulin
XPORT-MM-031, NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Hourglass Jul 2024 - Dec 2024 : H2'24 - Market entry in Malaysia in combination with bortezomib and dexamethasone for r/r MM
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
EVOLVE CLL/SLL, NCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), Study

Recruiting
3
247
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA 101, GA-101, GA101, Gazyva, huMAB(CD20), R 7159, R-7159, R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/28
10/28
DRAMMATIC, NCT04071457: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Hourglass Jan 2023 - Jun 2023 : From trial for patients with r/r multiple myeloma treated with an IMiD and PI
Recruiting
3
1100
Canada, US
Lenalidomide, CC-5013, Revlimid, Daratumumab/rHuPH20
SWOG Cancer Research Network, National Cancer Institute (NCI), Janssen, LP
Multiple Myeloma
07/29
07/40
VARIN, Stéphane
ROC-SPA, NCT03445845: Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

Completed
4
300
Europe, RoW
Secukinumab, TNF blocker, blood specimen
Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France
Axial Spondyloarthritis
09/24
10/24
NCT05848258: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Recruiting
2
380
Europe, US, RoW
LY3871801, Placebo
Eli Lilly and Company, Rigel Pharmaceuticals
Rheumatoid Arthritis
02/26
07/26
Scheid
XPORT-MM-031, NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
Hourglass Jul 2024 - Dec 2024 : H2'24 - Market entry in Malaysia in combination with bortezomib and dexamethasone for r/r MM
Recruiting
3
222
Europe, US
Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral
Stichting European Myeloma Network, Karyopharm Therapeutics Inc
Multiple Myeloma
03/26
03/29
CARTITUDE-6, NCT05257083 / 2021-003284-10: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Recruiting
3
750
Europe, Canada, Japan, US, RoW
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, JNJ-68284528, Cyclophosphamide, Fludarabine
Stichting European Myeloma Network, Janssen Research & Development, LLC
Multiple Myeloma
06/33
08/40
Moz, Luis Eduardo Silva
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RADICALPC, NCT03127631: A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Recruiting
N/A
6000
Canada, US, RoW
Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor
McMaster University, Prostate Cancer Canada, Canadian Cancer Society (CCS)
Prostate Cancer, Cardiovascular Disease
12/26
12/26
Wille, Julia
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

Active, not recruiting
3
1500
Europe, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Type 2 Diabetes
08/25
08/25
Herath, Sandaruwan
REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
3
20000
Europe, Canada, Japan, US, RoW
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, Nat Intensive Care Surveillance - MORU, National University Hospital, Singapore
Community-acquired Pneumonia, Influenza, COVID-19
02/26
02/28

Download Options